Clinical trial · Observational
Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma
NCT06725628CI-TRIAL-00083558not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Establish a predictive model for assessing neck lymph node metastasis of papillary thyroid carcinoma based on metabolomics, proteomics, and imaging omics data, exploring an ideal protocal for the precise diagnosis and treatment of papillary thyroid carcinoma."
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymph Node Cancer Metastatic | — | UNRESOLVED | — |
| Papillary Thyroid Carcinoma | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thy_CLNM_multi_omics | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- LNM group and NLNM group
- description
- The primary objective of this study is to evaluate the accuracy of the ThyMPR-CLNM model in predicting central lymph node metastasis (CLNM) in patients with stage T1 papillary thyroid carcinoma (PTC).
- interventionNames
- Diagnostic Test: Thy_CLNM_multi_omics
Primary outcomes (1)
- measure
- Lymph node metastasis status
- timeFrame
- Record lymph node metastasis status until the end of the surgery, followed by a one-year follow-up until the conclusion of the study.
- description
- Patients with thyroid cancer undergo thyroid cancer radical surgery according to the guidelines, with pathological results including the number of lymph node metastases and metastasis status, based on the final pathological diagnosis.
Secondary outcomes (1)
- measure
- Surgical complications and postoperative recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathological confirmation of PTC. 2. Patients who underwent primary surgery accompanied by central neck lymph node dissection. 3. Tumors measuring less than 2 cm in diameter. 4. Postoperative pathological reports including detailed information on the number of lymph nodes dissected and the number of metastatic lymph nodes. 5. Availability of comprehensive preoperative thyroid ultrasound images for analysis. Exclusion Criteria: 1. Postoperative pathological diagnosis indicating sub-types of PTC. 2. Tumor invasion into adjacent anatomic structures such as the sternothyroid muscle, surrounding soft tissues, trachea, esophagus, or laryngeal nerve. 3. History of neck trauma, previous tumor surgery, or adjuvant chemoradiotherapy. 4. Fewer than three lymph nodes dissected during surgery. 5. Concurrent acute inflammatory conditions or other hematologic disorders.
References
Publications (0)
Data not yet available
No reference posted for this study.